Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

By J. Rosenstock, E. Ferrannini. Diabetes Care, 2015

619 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/ce2c2a1dfe43c2d58a03002567a0469a052e8ea0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. Levine
2. E. Ferrannini

In Genetics

1. M. Levine

In Surgery

1. M. Levine
2. E. Ferrannini

Citations in the corpus

• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis (2016, background): “In patients with type 1 diabetes or insulin-treated patients with T2D who are receiving therapy with SGLT2 inhibitors, inappropriate reductions in exogenous insulin administration or intercurrent illness may precipitate episodes of nonhyperglycemic ketoacidosis (72).”
• Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials (2017, background): “Diabetic Ketoacidosis Reports of diabetic ketoacidosis (DKA) in patients treated with SGLT2 inhibitors have appeared for the three agents available in the United States (dapagliflozin, canagliflozin, and empagliflozin) [61-64], as well as others only available in Japan [65].”